Loading…
Cullinan Therapeutics, Inc. is projected to rise to $23.34 by 2027, a +29% move from its current price of $18.13. CGEM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $17.53 | $18.13 | $18.76 | +0.03% |
| Jul 14 | $17.29 | $18.14 | $19.03 | +0.05% |
| Jul 15 | $17.11 | $18.14 | $19.24 | +0.08% |
| Jul 16 | $16.96 | $18.15 | $19.42 | +0.11% |
| Jul 17 | $16.83 | $18.15 | $19.58 | +0.13% |
| Jul 18 | $16.72 | $18.16 | $19.73 | +0.16% |
| Jul 19 | $16.61 | $18.16 | $19.86 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.61 | $18.16 | $19.86 | +0.19% |
| Week 2 | $16.04 | $18.20 | $20.65 | +0.38% |
| Week 3 | $15.62 | $18.23 | $21.29 | +0.57% |
| Week 4 | $15.27 | $18.27 | $21.85 | +0.75% |
| Week 5 | $14.98 | $18.30 | $22.35 | +0.94% |
| Week 6 | $14.73 | $18.34 | $22.83 | +1.13% |
| Week 7 | $14.50 | $18.37 | $23.28 | +1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell engager in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, in Phase 1 clinical trials for relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc.
and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Therapeutics, Inc. (CGEM) operates as a healthcare company focused on autoimmune diseases and cancer therapeutics. It develops bispecific T cell engagers and targeted inhibitors, with multiple programs at Phase 1 and collaborations spanning licensing, co-development, and antibody optimization.
The organization is headquartered in Cambridge, Massachusetts and carries a market presence under the CGEM ticker with a current price of $17.30 and a market capitalization of $1.06B, ranked 2352 by market cap. The stock exhibits bullish technical sentiment, supported by a 14-day RSI near the upper range and key moving averages suggesting near-term strength.
A major floor 46.0% below — a decisive break under it would weaken the trend.
The nearest floor, 33.5% below — buyers have tended to step in here.
Price is pressing into resistance (1.9% away) — a breakout level to watch.
A major ceiling 24.9% above — clearing it would confirm fresh momentum.
Key CGEM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.18 | Sell | $18.16 | Sell |
| MA 10 | $18.08 | Buy | $17.86 | Buy |
| MA 20 | $16.77 | Buy | $17.10 | Buy |
| MA 50 | $15.51 | Buy | $15.86 | Buy |
| MA 100 | $14.84 | Buy | $14.68 | Buy |
| MA 200 | $12.22 | Buy | $13.14 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.63 | Neutral |
| Stoch RSI (14) | 27.38 | Neutral |
| CCI (20) | 52.55 | Neutral |
| Williams %R (14) | -29.17 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 2.14 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 70.83 | Neutral |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | 2.32 | Buy |
| Ultimate (7,14,28) | 56.89 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 18.43 | Sell |
| ADX (14) | 24.79 | Buy |
| ATR (14) | 0.43 | Info |
The near-term setup is bullish, with RSI(14) at 70 indicating strong momentum. The stock trades above both the SMA50 ($14.47) and the SMA200 ($11.47), signaling a constructive trend for the short term. Support sits at $12.05 while resistance is at $17.30, framing the immediate risk/reward, and the 30-day price range spans from $12.74 to $23.49.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $18.13 | $24.04 | 0% | Neutral | |
| $18.17 | $23.34 | $31.95 | +29% | Bullish | |
| $23.57 | $31.37 | $44.89 | +73% | Bullish | |
| $23.76 | $32.56 | $48.23 | +80% | Bullish | |
| $24.45 | $34.40 | $52.44 | +90% | Bullish | |
| $25.17 | $36.29 | $56.72 | +100% | Bullish | |
| $24.66 | $36.36 | $58.12 | +101% | Bullish | |
| $31.79 | $47.89 | $78.11 | +164% | Bullish | |
| $36.22 | $55.68 | $92.51 | +207% | Bullish | |
| $35.65 | $55.88 | $94.44 | +208% | Bullish | |
| $52.09 | $89.32 | $162.15 | +393% | Bullish | |
| $71.35 | $143.54 | $288.86 | +692% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.99 | $18.13 | $21.91 | +0.00% |
| August 2026 | $15.15 | $18.00 | $22.03 | -0.74% |
| September 2026 | $15.51 | $18.58 | $23.06 | +3.24% |
| October 2026 | $16.08 | $19.41 | $24.37 | +4.49% |
| November 2026 | $15.71 | $19.09 | $24.19 | -1.67% |
| December 2026 | $15.39 | $18.81 | $24.04 | -1.48% |
Click any year to see its month-by-month CGEM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cullinan Therapeutics, Inc.'s 2026 outlook centres on $18.13, within a $9.99 to $24.04 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGEM could reach as high as $31.95, with a base case around $23.34 and support toward $18.17 — roughly +29% from $18.13. Momentum favours further upside here.
Expect CGEM to range from $23.57 to $44.89 through 2028. The $31.37 average target implies a +73% move from current prices. That is up +34% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CGEM price prediction for 2029 points to an average of $32.56 (low $23.76, high $48.23) — a potential gain of +80% on today's $18.13. Momentum favours further upside here.
In 2030, CGEM is projected to trade between $24.45 and $52.44, averaging $34.40 — a potential gain of +90% from today's $18.13. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cullinan Therapeutics, Inc.'s 2031 outlook centres on $36.29, within a $25.17 to $56.72 range. That is up +5% on the projected 2030 average. That marks a +100% change versus current levels. Momentum favours further upside here.
By 2032, CGEM could reach as high as $58.12, with a base case around $36.36 and support toward $24.66 — roughly +101% from $18.13. Buyers look set to stay in control over this stretch.
Expect CGEM to range from $31.79 to $78.11 through 2033. The $47.89 average target implies a +164% move from current prices. That is up +32% on the projected 2032 average. Momentum favours further upside here.
The CGEM price prediction for 2034 points to an average of $55.68 (low $36.22, high $92.51) — a potential gain of +207% on today's $18.13. Buyers look set to stay in control over this stretch.
In 2035, CGEM is projected to trade between $35.65 and $94.44, averaging $55.88 — a potential gain of +208% from today's $18.13. That is up 0% on the projected 2034 average. Momentum favours further upside here.
Cullinan Therapeutics, Inc.'s 2040 outlook centres on $89.32, within a $52.09 to $162.15 range. That is up +60% on the projected 2035 average. That marks a +393% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGEM could reach as high as $288.86, with a base case around $143.54 and support toward $71.35 — roughly +692% from $18.13. Momentum favours further upside here.
Investing $1,000 in CGEM today (≈ 55.157198 CGEM) could be worth
$7,917.33
+$6,917.33 (+692%) by 2050 · US Dollar
Based on the average projected CGEM price of $143.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGEMwould be worth at today's price.
$1,000 invested in CGEM on Jul 10, 2025 (≈ 127.551018 CGEM) would be worth
$2,312.5
+$1,312.5 (+131.2%) today · 2.31× · US Dollar
Based on a CGEM entry price of $7.84 vs. today's $18.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.63 | $1,028.36 | +2.8% |
| 1 month ago | $12.05 | $1,504.56 | +50.5% |
| 3 months ago | $14.54 | $1,246.91 | +24.7% |
| 6 months ago | $10.61 | $1,708.77 | +70.9% |
| 1 year ago | $7.84 | $2,312.5 | +131.2% |
| All time (5.0y) ago | $29.65 | $611.47 | -38.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEM forecast.
Our base-case forecast reaches $36.00 around 2031.
Implied market cap at $36.00: $2.21B
The multi-year forecast shows a path of substantial upside. In 2026, the average price is $17.30 with a min of $9.99 and a max of $25.08, and an ROI of 0% (neutral sentiment). From 2027 onward, the outlook becomes increasingly bullish, with the average rising to $25.40 in 2027 (ROI 46.8), $34.83 in 2028 (ROI 101.3), $37.01 in 2029 (ROI 114), and $37.83 in 2030 (ROI 118.7).
The uptrend continues through 2031 ($39.48, ROI 128.2) and 2032 ($41.96, ROI 142.6). The forecast accelerates in 2033 ($58.71, ROI 239.3) and 2034 ($67.64, ROI 291), then in 2035 ($69.28, ROI 300.5). Long-range projections show the strongest gains in 2040 ($115.44, ROI 567.3) and 2050 ($188.25, ROI 988.2).
While these figures imply meaningful upside, they are estimates and not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $37.83, with a potential range of $24.59 to $62.90 and an ROI of 118.7%, with bullish sentiment.
The forecast shows a neutral stance in 2026, followed by a bullish trajectory from 2027 onward, with the average price rising to $69.28 by 2035 and to $188.25 by 2050, and ROIs reaching 988.2%. These are estimates and carry uncertainty.
Yes. The forecasted maximum prices reach $106.16 in 2033, $125.15 in 2034, $130.91 in 2035, $237.91 in 2040, and $432.98 in 2050, indicating the potential to exceed $100 in multiple years.
The current price is $17.30 per share and the market capitalization is $1.06B.
The 30-day range is from $12.74 to $23.49.
Cullinan Therapeutics, Inc. Community Discussion
0Share your Cullinan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.